HER2 Status in Low-grade Serous Ovarian Tumors-Reference-Cited by-同舟云学术

HER2 Status in Low-grade Serous Ovarian Tumors

Published:2024-07-30 Issue: Volume: Page:
ISSN:0277-1691
Container-title:International Journal of Gynecological Pathology
language:en
Short-container-title:

Author:

Němejcová Kristýna¹,Šafanda Adam¹,Kendall Bártů Michaela¹,Hájková Nikola¹,Drozenová Jana²,Fabian Pavel³,Laco Jan⁴,Matěj Radoslav¹²⁵,Méhes Gábor⁶,Škapa Petr⁷,Stružinská Ivana¹,Dundr Pavel¹

Affiliation:

1. Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic

2. Department of Pathology, Charles University, 3rd Faculty of Medicine, University Hospital Královské Vinohrady, Prague, Czech Republic

3. Department of Oncological Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic

4. The Fingerland Department of Pathology, Charles University Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Czech Republic

5. Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University, Thomayer University Hospital, Prague, Czech Republic

6. Department of Pathology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary

7. Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic

Abstract

Using immunohistochemistry, we examined a large cohort of 135 ovarian tumors, made up of 96 low-grade serous carcinomas (LGSCs) and 39 serous borderline tumors (micropapillary variant, mSBT), with the aim of exploring their HER2 status (overexpression). We followed with comprehensive genomic analyses on this sample set from our previous study, which revealed HER2 mutation in 5% (4/75) of LGSC and 10% (3/29) of mSBT. No cases were evaluated as HER2-positive, but 6 LGSCs and 1 mSBT were scored as HER2 1+, and 2 LGSCs and 1 mSBT showed the so-called HER2 “ultra-low” phenotype. This could be of clinical value as a potential therapeutical target concerning emerging therapeutic treatments (antibody conjugates). However, the clinical significance of this expression still needs to be established.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference31 articles.

1. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary;Gershenson;Obstet Gynecol,2006

2. Low-grade Serous carcinoma of the ovary: clinicopathologic analysis of 52 invasive cases and identification of a possible noninvasive intermediate lesion;Ahn;Am J Surg Pathol,2016

3. Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities;Cheasley;J Pathol,2021

4. Therapeutic Advances and challenges in the management of HER2-positive gastroesophageal cancers;Chuang;Diseases,2022

5. HER2 activating mutations are targets for colorectal cancer treatment;Kavuri;Cancer Discov,2015